Why the study?
Does postprocedural suboptimal TIMI flow (grade ≤ 2) worsen long-term major adverse cardiac events compared to normal TIMI flow (grade 3) in patients with acute myocardial infarction undergoing PCI?
Does postprocedural suboptimal TIMI flow (grade ≤ 2) worsen long-term major adverse cardiac events compared to normal TIMI flow (grade 3) in patients with acute myocardial infarction undergoing PCI?
Answers are grounded in this paper and cite their sources.
Suboptimal postprocedural TIMI flow (≤ 2) after PCI is associated with increased long-term mortality and MACE in patients with STEMI, but does not significantly impact long-term outcomes in patients with NSTEMI.
This study aimed to evaluate the clinical prognostic implications of postprocedural Thrombolysis in Myocardial Infarction (TIMI) flow in acute myocardial infarction patients. A total of 2796 ST-elevation myocardial infarction (STEMI) and 1720 non ST-elevation myocardial infarction (NSTEMI) patients treated in 8 hospitals affiliated with the Catholic University of Korea and Chonnam National University Hospital were analyzed. The study populations were divided according to the final TIMI flow. The primary outcome were the major adverse cardiac events (MACE), defined as a composite of cardiac deaths (CD), nonfatal myocardial infarctions (MI), and target lesion revascularization (TLR). Over a median follow-up of 3.3 years (minimum 2 to maximum 5 years), MACE and CD occurred more frequently in STEMI patients with TIMI ≤ 2 group than those with TIMI 3 (MACE: adjusted hazard ratio [aHR], 1.962; 95% confidence interval [CI] 1.513 to 2.546, P < 0.001, CD: aHR, 3.154, CI 2.308 to 4.309, P < 0.001). However, there was no significant difference between the two subgroups in NSTEMI (aHR, 0.932; 95% CI 0.586 to 1.484, P = 0.087). In STEMI patients, good postprocedural TIMI flow after PCI was associated with favorable clinical outcomes. And the effect of poor TIMI flow in STEMI was on death, not the components of MACE. Meanwhile, postprocedural TIMI flow had no effect on long-term outcomes in NSTEMI patients.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: